Clinical trial · Observational
The Value of TFF3 in Diagnosis of Gastric Cancer
The Value of Serum Trefoil Factor Family 3 (TFF3) in Diagnosis of Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gastric cancer (GC), is a cancer developing from the inner lining of the stomach .The most common cause is infection by the bacterium Helicobacter pylori,which accounts for 60% of cases. Human pepsinogens (HP) are proenzymes for pepsin; digestive enzymes produced by gastric chief cells, classified into two groups: pepsinogen I (PGI) and pepsinogen II (PGII), humen pepsinogens considered promising serological biomarkers for the screening of atrophic gastritis and gastric cancer. The trefoil factor family (TFF) of peptides comprises small (12-22kDa) molecules that are secreted by the mammalian gastro-intestinal tract.Trefoil factor family 3 (TFF3) is a more stable non invasive biomarker of gastric cancer risk even in early gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group:1
- description
- Gastric cancer patients
- interventionNames
- Diagnostic Test: Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)
- label
- Group:2
- description
- Patients with benign gastric diseases
- interventionNames
- Diagnostic Test: Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)
Primary outcomes (1)
- measure
- Diagnostic value of trefoil factor family 3 (TFF3) in serum of gastric cancer as non invasive marker
- timeFrame
- 2 day
- description
- Measurement of TFF3 by enzyme linked immunosorbent assay (ELISA) in serum of gastric cancer patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Includes all patients presented by gastric cancer with clinical, radiological, laboratory diagnosis and pathological diagnosis. * Individuals with benign diseases such as gastric polyps ,leiomyomas, gastric ulcers, atrophic gastritis and gastritis clinical, radiological, laboratory and pathological diagnosis. Exclusion Criteria: * \- Previous upper gastrointestinal surgery, patients with gastric cancer that had been received chemotherapy, radiotherapy or surgical treatment. * Patients simultaneously presented with a malignancy other than that of the stomach (Breast, pancreatic or colorectal). * Pateints with severe systemic co-morbidities such as cardiopulmonary,hepatic and renal diseases
References
Publications (3)
- BACKGROUNDChoi IJ. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc. 2014 Nov;47(6):497-503. doi: 10.5946/ce.2014.47.6.497. Epub 2014 Nov 30. PMID 25505714
- BACKGROUNDLee JY, Park KS, Lee HG, Baek WK, Cho KB, Lee YJ, Lee YS, Ryu SW. Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer. Clin Exp Med. 2017 Aug;17(3):403-410. doi: 10.1007/s10238-016-0426-1. Epub 2016 May 6. PMID 27154568
- BACKGROUNDXiao P, Ling H, Lan G, Liu J, Hu H, Yang R. Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer. Clin Chim Acta. 2015 Oct 23;450:127-34. doi: 10.1016/j.cca.2015.08.004. Epub 2015 Aug 8. PMID 26265233